Options Update: Myriad Genetics (MYGN) & ADC Telecomm (ADCT)
Myriad Genetics (MYGN)
MYGN Volatility Up Into Alzheimer's Data
MYGN is recently trading at $48.71.
MYGN's Flurizan, a treatment for Alzheimer's diseases, is expected to release top-line results in June.
MYGN June option implied volatility of 105 is above its 6-month average of 63, suggesting larger price uncertainty.
ADC Telecomm (ADCT)
ADCT Volatility Flat Into EPS
ADCT is recently up $.50 to $16.17 in pre-open trading.
ADCT is scheduled to report Q2 EPS on June 4.
JP Morgan upgraded ADCT to Overweight from Neutral.
ADCT June option implied volatility of 52 is near its 6-month average, suggesting non-directional price risk.
"
About Paul Foster
Paul Foster is a former member of the Chicago Board Options Exchange with 21-years of professional experience in the capital markets, investments, trading, corporate finance, arbitrage, options and mergers & acquisitions. His writing about the options market has appeared in a wide variety of publications.
View Paul Foster's post archive >
